is supported by the American Heart AssociationBristol Myers Squibb Foundation through the Winn Diversity in Clinical Trials Clinical Investigator Leadership Award, and by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Physician-Scientist Career Development Award, Grant Number K12DK133995 (David Maahs, Linda DiMeglio, Multi-Center Program Directors)
2 See full Indication, including limitations of use and full Important Safety Information below
Therefore, drugs that rely on timely absorption in the small intestine may not work as expected
Always consult the batterys datasheet or label before exceeding 1C
These alternate metabolic routes lead to accumulation of toxic intermediates and advanced glycation end products, promoting inflammation, cellular dysfunction, apoptosis, and fibrosis within kidney tissues [24,25]
step therapy required BCBS of Illinois Covered with PA BMI criteria + documented diet/exercise failure BCBS of Michigan Not covered (fully insured) Removed all GLP-1 weight loss drugs from commercial plans Jan 2025 BCBS of Florida (Florida Blue) Covered with PA BMI 30